IRADIMED Dirección

Dirección controles de criterios 4/4

El CEO de IRADIMED's es Roger Susi , nombrado en Jan 2004, tiene una permanencia de 20.25 años. compensación anual total es $586.04K, compuesta por 49.5% salario y 50.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 36.23% de las acciones de la empresa, por valor de $190.26M. La antigüedad media del equipo directivo y de la junta directiva es de 2.8 años y 7.8 años, respectivamente.

Información clave

Roger Susi

Chief Executive Officer (CEO)

US$642.6k

Compensación total

Porcentaje del salario del CEO	47.9%
Permanencia del CEO	20.3yrs
Participación del CEO	36.2%
Permanencia media de la dirección	2.8yrs
Promedio de permanencia en la Junta Directiva	7.9yrs

Actualizaciones recientes de la dirección

Recent updates

If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity

Feb 23

At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?

Feb 05

Iradimed withdraws FDA filing for new infusion pump; prelim Q3 revenue rises 13% Y/Y

Oct 10

IRadimed: Record Revenue Could Translate To Share Price Appreciation

Aug 23

Here's Why We Think IRadimed (NASDAQ:IRMD) Is Well Worth Watching

Aug 17

iRadimed Non-GAAP EPS of $0.26 beats by $0.02, revenue of $12.7M beats by $0.06M

Jul 29

IRadimed: Reduce Equity Beta With Upside Capture

Jul 18

IRadimed (NASDAQ:IRMD) Might Be Having Difficulty Using Its Capital Effectively

Jul 13

At US$48.60, Is IRadimed Corporation (NASDAQ:IRMD) Worth Looking At Closely?

Feb 05

Here's What's Concerning About IRadimed's (NASDAQ:IRMD) Returns On Capital

Jan 12

Returns On Capital At IRadimed (NASDAQ:IRMD) Paint A Concerning Picture

Jul 13

iRadimed EPS beats by $0.04, beats on revenue

Apr 30

iRadimed EPS misses by $0.02, beats on revenue

Feb 04

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Roger Susi en comparación con los beneficios de IRADIMED?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	US$18m
Dec 31 2023	US$643k	US$308k	US$17m
Sep 30 2023	n/a	n/a	US$16m
Jun 30 2023	n/a	n/a	US$15m
Mar 31 2023	n/a	n/a	US$14m
Dec 31 2022	US$586k	US$290k	US$13m
Sep 30 2022	n/a	n/a	US$13m
Jun 30 2022	n/a	n/a	US$12m
Mar 31 2022	n/a	n/a	US$10m
Dec 31 2021	US$615k	US$308k	US$9m
Sep 30 2021	n/a	n/a	US$6m
Jun 30 2021	n/a	n/a	US$5m
Mar 31 2021	n/a	n/a	US$987k
Dec 31 2020	US$435k	US$290k	US$1m
Sep 30 2020	n/a	n/a	US$4m
Jun 30 2020	n/a	n/a	US$5m
Mar 31 2020	n/a	n/a	US$10m
Dec 31 2019	US$488k	US$288k	US$10m
Sep 30 2019	n/a	n/a	US$8m
Jun 30 2019	n/a	n/a	US$8m
Mar 31 2019	n/a	n/a	US$7m
Dec 31 2018	US$495k	US$279k	US$6m
Sep 30 2018	n/a	n/a	US$5m
Jun 30 2018	n/a	n/a	US$3m
Mar 31 2018	n/a	n/a	US$2m
Dec 31 2017	US$474k	US$268k	US$500k

Compensación vs. Mercado: La compensación total de Roger($USD586.04K) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD2.37M).

Compensación vs. Ingresos: La compensación de Roger ha sido consistente con los resultados de la empresa en el último año.

CEO

Roger Susi (70 yo)

20.3yrs

Permanencia

US$642,566

Compensación

Mr. Roger E. Susi serves as President and Chief Executive Officer of IRadimed Corporation since May 28, 2020. He founded IRadimed Corporation in 2004 and has been its Chairman of the Board since June 10, 2...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Roger Susi	Founder	20.3yrs	US$642.57k	36.23% $ 200.0m
John Glenn	CFO & Corporate Secretary	1.9yrs	US$1.27m	0.054% $ 300.0k
Randy Waddell	Vice President of Worldwide Sales & Marketing	2.8yrs	US$597.28k	0.047% $ 260.7k
Chris Williamson	Executive Vice President of Continuous Improvement & Information Technology	1.9yrs	sin datos	sin datos
Matt Garner	Controller	4.3yrs	sin datos	sin datos
Steve Kachelmeyer	Vice President of Regulatory Affairs & Quality Assurance	no data	US$425.08k	0.042% $ 229.9k
Lynn Neuhardt	Vice President of Research & Development	no data	US$442.20k	0.050% $ 276.8k

2.8yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de IRMD se considera experimentado (2.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Roger Susi	Founder	7.9yrs	US$642.57k	36.23% $ 200.0m
James Hawkins	Director	4.9yrs	US$159.36k	0.31% $ 1.7m
Anthony Vuoto	Independent Director	8.2yrs	US$167.48k	0.13% $ 737.7k
Monty Allen	Independent Director	10.3yrs	US$169.98k	0.16% $ 871.8k
Hilda Scharen-Guivel	Independent Director	1.6yrs	US$153.11k	0.014% $ 77.0k

7.9yrs

Permanencia media

70yo

Promedio de edad

Junta con experiencia: La junta directiva de IRMD se considera experimentada (7.8 años de antigüedad promedio).

IRADIMED Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

IRADIMED CORPORATION, Annual General Meeting, Jun 20, 2024

Director notifies of intention to sell stock

Director notifies of intention to sell stock

Independent Director recently sold US$122k worth of stock

Founder notifies of intention to sell stock

Founder notifies of intention to sell stock

Recent updates

IRADIMED CORPORATION Declares Regular Quarterly Cash Dividend, Payable on May 30, 2024

Now 25% overvalued

IRADIMED CORPORATION, Annual General Meeting, Jun 20, 2024

IRADIMED CORPORATION to Report Q1, 2024 Results on May 02, 2024

Now 21% overvalued

Now 21% overvalued after recent price rise

If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

IRadimed Corporation Provides Revenue Guidance for the First Quarter and Full Year of 2024

Getting In Cheap On IRadimed Corporation (NASDAQ:IRMD) Is Unlikely

IRadimed Corporation to Report Q4, 2023 Results on Feb 08, 2024

Director notifies of intention to sell stock

IRadimed Corporation Approves Initiation of Regular Quarterly Dividend, Payable on January 12, 2024

Director notifies of intention to sell stock

Independent Director recently sold US$122k worth of stock

Should You Investigate IRadimed Corporation (NASDAQ:IRMD) At US$45.06?

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Iradimed Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

IRadimed Corporation to Report Q3, 2023 Results on Nov 03, 2023

Founder notifies of intention to sell stock

Calculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)

Price target increased by 9.5% to US$57.50

IRadimed Corporation Provides Earnings Guidance for the Third Quarter and for the Full Year of 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

IRadimed Corporation to Report Q2, 2023 Results on Aug 03, 2023

Founder notifies of intention to sell stock

Independent Director recently sold US$128k worth of stock

Price target increased by 14% to US$52.50

IRadimed Corporation Revises Earnings Guidance for the Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorates as stock falls 16%

At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Iradimed Corporation Approves Special Cash Dividend, Payable on February 21, 2023

IRadimed Corporation to Report Q4, 2022 Results on Feb 02, 2023

Investor sentiment improves as stock rises 16%

Price target increased to US$46.00

IRadimed Corporation Provides Earnings Guidance for the First Quarter of 2023 and Full Year 2023

Independent Director exercised options to buy US$87k worth of stock.

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Iradimed Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

IRadimed Corporation to Report Q3, 2022 Results on Nov 03, 2022

IRadimed Corporation Provides Revenue Guidance for the Third Quarter Ended September 30, 2022

Iradimed withdraws FDA filing for new infusion pump; prelim Q3 revenue rises 13% Y/Y

IRadimed Corporation Announces Board Changes

IRadimed: Record Revenue Could Translate To Share Price Appreciation

Investor sentiment deteriorated over the past week

Here's Why We Think IRadimed (NASDAQ:IRMD) Is Well Worth Watching

Independent Director recently sold US$116k worth of stock

Insufficient new directors

Iradimed Corporation Revises Earnings Guidance for the Full Year 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations

iRadimed Non-GAAP EPS of $0.26 beats by $0.02, revenue of $12.7M beats by $0.06M

IRadimed Corporation to Report Q2, 2022 Results on Jul 29, 2022

IRadimed: Reduce Equity Beta With Upside Capture

IRadimed (NASDAQ:IRMD) Might Be Having Difficulty Using Its Capital Effectively

Insufficient new directors

IRadimed Corporation Names John F. Glenn as Chief Financial Officer, Effective on or before June 20, 2022

Price target decreased to US$40.00

Iradimed Corporation Revises Earnings Guidance for the Full Year 2022

First quarter 2022 earnings: EPS exceeds analyst expectations

Price target increased to US$53.00

IRadimed Corporation to Report Q1, 2022 Results on Apr 29, 2022

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS exceeds analyst expectations

Independent Director notifies of intention to sell stock

COO, CFO & Secretary recently sold US$965k worth of stock

Investor sentiment improved over the past week

IRadimed Corporation Announces Special Share Cash Dividend, Payable on February 24, 2022